Woo Sung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Woo Sung Kim has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Chae-Man Lim
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-Gil, Songpa-gu, Seoul 05505, Republic of Korea
3 shared publications - Sang Do Lee
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
3 shared publications - Chang-Min Choi
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea
2 shared publications - Dae Ho Lee
Department of Oncology, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea
2 shared publications Dong Soon Kim
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
2 shared publications- Jae Cheol Lee
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
2 shared publications
Latest Publications
- Open Access
- 7 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
Pemetrexed is widely used for the treatment of advanced non-squamous non-small-cell lung cancer (NSCLC). However, factors that can predict the benefits of pemetrexed therapy have not yet been defined. We compared the clinical and molecule pathological characteristics of good and poor responders among a cohort of 1,848 non-squamous NSCLC patients who had received at least two cycles of pemetrexed therapy between November 2006 and February 2015. Among these cases, 92 good responders who were the top 5 % in terms of progression-free survival (PFS) and 222 poor responders who had progressive disease after only 2 cycles of therapy were selected for the analysis. The median PFS of the good responders was 29.9 months (range; 20.9–90.0) and the median number of cycle was 37 (range; 18–129). Although 53.5 % of patients showed stable disease (SD), this response was sustained (median PFS in SD, 29.6 months). A never-smoking status was related to better survival outcome, whereas EGFR mutation, two or more metastatic sites, and intra-abdominal metastasis were each associated with a poor PFS. ALK translocation showed a tendency for a positive impact on response to pemetrexed, whereas metastatic lesion to liver, adrenal gland or bone showed a tendency for a negative impact despite not reaching our threshold for statistical significance. Predictive factors, such as smoking status, the status of genetic alteration and tumor burden, should be considered when administering pemetrexed therapy for non-squamous NSCLC.
- 7 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Open AccessPredictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
Pemetrexed is widely used for the treatment of advanced non-squamous non-small-cell lung cancer (NSCLC). However, factors that can predict the benefits of pemetrexed therapy have not yet been defined. We compared the clinical and molecule pathological characteristics of good and poor responders among a cohort of 1,848 non-squamous NSCLC patients who had received at least two cycles of pemetrexed therapy between November 2006 and February 2015. Among these cases, 92 good responders who were the top 5 % in terms of progression-free survival (PFS) and 222 poor responders who had progressive disease after only 2 cycles of therapy were selected for the analysis. The median PFS of the good responders was 29.9 months (range; 20.9–90.0) and the median number of cycle was 37 (range; 18–129). Although 53.5 % of patients showed stable disease (SD), this response was sustained (median PFS in SD, 29.6 months). A never-smoking status was related to better survival outcome, whereas EGFR mutation, two or more metastatic sites, and intra-abdominal metastasis were each associated with a poor PFS. ALK translocation showed a tendency for a positive impact on response to pemetrexed, whereas metastatic lesion to liver, adrenal gland or bone showed a tendency for a negative impact despite not reaching our threshold for statistical significance. Predictive factors, such as smoking status, the status of genetic alteration and tumor burden, should be considered when administering pemetrexed therapy for non-squamous NSCLC.
- Open Access
- 27 December 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 1-8
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
Background: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. Methods: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal transition (EMT) and neuroendocrine markers by immunohistochemistry. Results: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M mutation showed a more favorable prognosis. Conclusion: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance are necessary.
- 27 December 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 1-8
Open AccessMechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
Background: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. Methods: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal transition (EMT) and neuroendocrine markers by immunohistochemistry. Results: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M mutation showed a more favorable prognosis. Conclusion: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance are necessary.
- Open Access
- 1 January 2009
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 67 (6)
A Case of Yellow Nail Syndrome Manifesting as Chronic Recurrent Pleural Effusion
- 1 January 2009
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 67 (6)
Open AccessA Case of Yellow Nail Syndrome Manifesting as Chronic Recurrent Pleural Effusion
- Open Access
- 1 January 2009
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 66 (3) , 173-177
Cardovascular Impacts of Sleep-disordered Breathing
- 1 January 2009
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 66 (3) , 173-177
Open AccessCardovascular Impacts of Sleep-disordered Breathing
- Open Access
- 19 January 2008
- Published by Springer Nature in Critical Care
- Vol. 12 (1) , R6
Diagnostic utility of the soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid from patients with bilateral lung infiltrates
Background: Differential diagnosis of patients with bilateral lung infiltrates remains a difficult problem for intensive care clinicians. Here we evaluate the diagnostic role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in bronchoalveolar lavage (BAL) specimens from patients with bilateral lung infiltrates. Methods: We conducted a prospective observational study on 80 patients with bilateral lung infiltrates with clinical suspicion of infectious pneumonia. Patients were categorized into three groups: bacterial or fungal infection, intracellular or viral infection, and noninfectious inflammatory disease. sTREM-1 concentrations were measured, and BAL fluid and Clinical Pulmonary Infection Score (CPIS) were analyzed. Results: The sTREM-1 concentration was significantly increased in patients with bacterial or fungal pneumonia (n = 29, 521.2 ± 94.7 pg/ml), compared with that in patients with viral pneumonia, atypical pneumonia or tuberculosis (n = 14, 92.9 ± 20.0 pg/ml) or noninfectious inflammatory disease (n = 37, 92.8 ± 10.7 pg/ml). The concentration of sTREM-1 in BAL fluid, but not CPIS, was an independent predictor of bacterial or fungal pneumonia, and a cutoff value of more than 184 pg/ml yielded a diagnostic sensitivity of 86% and a specificity of 90%. Conclusion: The sTREM-1 level in BAL fluid from patients with bilateral lung infiltrates is a potential marker for the differential diagnosis of pneumonia due to extracellular bacteria.
- 19 January 2008
- Published by Springer Nature in Critical Care
- Vol. 12 (1) , R6
Open AccessDiagnostic utility of the soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid from patients with bilateral lung infiltrates
Background: Differential diagnosis of patients with bilateral lung infiltrates remains a difficult problem for intensive care clinicians. Here we evaluate the diagnostic role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in bronchoalveolar lavage (BAL) specimens from patients with bilateral lung infiltrates. Methods: We conducted a prospective observational study on 80 patients with bilateral lung infiltrates with clinical suspicion of infectious pneumonia. Patients were categorized into three groups: bacterial or fungal infection, intracellular or viral infection, and noninfectious inflammatory disease. sTREM-1 concentrations were measured, and BAL fluid and Clinical Pulmonary Infection Score (CPIS) were analyzed. Results: The sTREM-1 concentration was significantly increased in patients with bacterial or fungal pneumonia (n = 29, 521.2 ± 94.7 pg/ml), compared with that in patients with viral pneumonia, atypical pneumonia or tuberculosis (n = 14, 92.9 ± 20.0 pg/ml) or noninfectious inflammatory disease (n = 37, 92.8 ± 10.7 pg/ml). The concentration of sTREM-1 in BAL fluid, but not CPIS, was an independent predictor of bacterial or fungal pneumonia, and a cutoff value of more than 184 pg/ml yielded a diagnostic sensitivity of 86% and a specificity of 90%. Conclusion: The sTREM-1 level in BAL fluid from patients with bilateral lung infiltrates is a potential marker for the differential diagnosis of pneumonia due to extracellular bacteria.
- Open Access
- 1 January 2004
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 57 (3)
The Adjuvant Effect of Subcutaneous Interferon-gamma in the Treatment of Refractory Multidrug-resistant Pulmonary Tuberculosis
- 1 January 2004
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 57 (3)
Open AccessThe Adjuvant Effect of Subcutaneous Interferon-gamma in the Treatment of Refractory Multidrug-resistant Pulmonary Tuberculosis
- Open Access
- 1 January 2003
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 55 (2)
Cardiopulmonary Exercise Testing: Application to Pulmonary Rehabilitation
- 1 January 2003
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 55 (2)
Open AccessCardiopulmonary Exercise Testing: Application to Pulmonary Rehabilitation
- Open Access
- 1 January 2002
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 53 (1)
A Case of Metastatic Non-small Cell Lung Cancer Presenting with Numb Chin Syndrome
- 1 January 2002
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 53 (1)
Open AccessA Case of Metastatic Non-small Cell Lung Cancer Presenting with Numb Chin Syndrome